Actively Recruiting
fMRI Neurofeedback With Matter Neuroscience App
Led by Stanford University · Updated on 2025-12-17
240
Participants Needed
1
Research Sites
148 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Study will utilize an app, Matter Neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. We hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.
CONDITIONS
Official Title
fMRI Neurofeedback With Matter Neuroscience App
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female between 18 and 80 years old at screening
- Primary diagnosis of nonpsychotic major depressive disorder without psychotic features
- Montgomery-Åsberg Depression Rating Scale (MADRS) score between 15 and 25
- Able to read, understand, and provide written informed consent, with English proficiency to complete questionnaires and follow instructions
- Possess an iPhone with the latest compatible iOS version and able to use the study app
- History of 1 to 5 adequate antidepressant medication failures
- Stable dose of primary antidepressant medication for 4 weeks before baseline and willing to continue throughout the study
- In good general health as determined by medical history and study physician
- Women of reproductive potential agree to use highly effective contraception during participation
- Adequate vision (with or without corrective lenses) to view study materials in the MRI
- Agree to adhere to lifestyle considerations throughout the study duration
You will not qualify if you...
- Contraindication to MRI such as ferromagnetic metal in the body
- Severe claustrophobia
- Pregnant, breastfeeding, positive pregnancy test, or planning pregnancy during the study
- Primary psychiatric condition other than major depressive disorder requiring treatment, except stable anxiety disorder
- History or current psychotic disorder, schizophrenia, psychosis, bipolar disorder, or severe borderline personality disorder
- Diagnosis of intellectual disability, autism spectrum disorder, or other neurodevelopmental disorder
- Current moderate or severe substance use disorder or signs of acute withdrawal
- Positive urine test for recent recreational drug use
- Considered at significant risk for suicide during the study
- Recent or concurrent use of rapid acting antidepressant treatments like ECT or TMS, excluding ketamine
- History of significant neurological diseases such as dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or significant head trauma
- Untreated or insufficiently treated endocrine or metabolic disorders
- Any condition deemed by the principal doctor to interfere with the study or increase participant risk
- Alexithymia as determined by the Toronto Alexithymia Scale
- Treatment with investigational drugs or other interventions during the study period
- Not currently experiencing a major depressive episode as defined by the MINI
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University Brain Stimulation Lab
Stanford, California, United States, 94304
Actively Recruiting
Research Team
N
Nick Bassano, MS
CONTACT
N
Noriah Johnson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here